Suchergebnisse - "NIVOLUMAB"

Five-Year Follow-Up of Patients With Relapsed and Refractory Classic Hodgkin Lymphoma Treated With Low-Dose Nivolumab (40 mg): A Matched Cohort Study With Standard-Dose Therapy.

Autoren: Fedorova L Lepik K Kotselyabina P et al.

Quelle: Hematological oncology [Hematol Oncol] 2025 Nov; Vol. 43 (6), pp. e70146.

Publikationsart: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article

Info zur Zeitschrift: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 8307268 Publication Model: Print Cited Medium: Internet ISSN: 1099-1069 (Electronic) Linking ISSN: 02780232 NLM ISO Abbreviation: Hematol Oncol Subsets: MEDLINE

MeSH-Schlagworte: Antineoplastic Agents, Immunological*/therapeutic use , Antineoplastic Agents, Immunological*/administration & dosage , Antineoplastic Agents, Immunological*/adverse effects , Hodgkin Disease*/drug therapy , Hodgkin Disease*/mortality , Hodgkin Disease*/pathology , Immune Checkpoint Inhibitors*/therapeutic use , Immune Checkpoint Inhibitors*/administration & dosage , Immune Checkpoint Inhibitors*/adverse effects , Nivolumab*/administration & dosage , Nivolumab*/therapeutic use , Nivolumab*/adverse effects, Adolescent ; Adult ; Aged ; Female ; Humans ; Male ; Middle Aged ; Young Adult ; Follow-Up Studies ; Survival Rate

Characterization of Patients with Lymph Node Only Metastatic Urothelial Carcinoma Treated with Nivolumab Plus Gemcitabine-Cisplatin Versus Gemcitabine-Cisplatin Alone from the CheckMate 901 Trial.

Autoren: Galsky MD van der Heijden MS Powles T et al.

Quelle: European urology [Eur Urol] 2025 Oct; Vol. 88 (4), pp. 325-330. Date of Electronic Publication: 2025 May 20.

Publikationsart: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Comparative Study; Multicenter Study

Info zur Zeitschrift: Publisher: Elsevier Science Country of Publication: Switzerland NLM ID: 7512719 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-7560 (Electronic) Linking ISSN: 03022838 NLM ISO Abbreviation: Eur Urol Subsets: MEDLINE

MeSH-Schlagworte: Cisplatin*/administration & dosage , Cisplatin*/adverse effects , Deoxycytidine*/analogs & derivatives , Deoxycytidine*/administration & dosage , Deoxycytidine*/adverse effects , Nivolumab*/administration & dosage , Nivolumab*/adverse effects , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects , Carcinoma, Transitional Cell*/drug therapy , Carcinoma, Transitional Cell*/secondary , Carcinoma, Transitional Cell*/mortality , Urologic Neoplasms*/drug therapy , Urologic Neoplasms*/pathology , Urologic Neoplasms*/mortality , Urinary Bladder Neoplasms*/drug therapy , Urinary Bladder Neoplasms*/pathology , Urinary Bladder Neoplasms*/mortality, Humans ; Gemcitabine ; Male ; Female ; Aged ; Middle Aged ; Lymphatic Metastasis ; Adult ; Treatment Outcome ; Progression-Free Survival

Efficacy and safety of a reduced starting dose of cabozantinib (20 mg) plus nivolumab for renal cell carcinoma in real-world practice.

Autoren: Sazuka T Watanabe Y Yokochi F et al.

Quelle: Japanese journal of clinical oncology [Jpn J Clin Oncol] 2025 Dec 03; Vol. 55 (12), pp. 1391-1396.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: Oxford University Press Country of Publication: England NLM ID: 0313225 Publication Model: Print Cited Medium: Internet ISSN: 1465-3621 (Electronic) Linking ISSN: 03682811 NLM ISO Abbreviation: Jpn J Clin Oncol Subsets: MEDLINE

MeSH-Schlagworte: Carcinoma, Renal Cell*/drug therapy , Carcinoma, Renal Cell*/pathology , Anilides*/administration & dosage , Anilides*/adverse effects , Nivolumab*/administration & dosage , Nivolumab*/adverse effects , Pyridines*/administration & dosage , Pyridines*/adverse effects , Kidney Neoplasms*/drug therapy , Kidney Neoplasms*/pathology , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects , Antineoplastic Combined Chemotherapy Protocols*/administration & dosage, Humans ; Male ; Female ; Aged ; Retrospective Studies ; Aged, 80 and over ; Middle Aged ; Treatment Outcome

Prolonged in-use physicochemical and biological stability of nivolumab and pembrolizumab diluted in saline infusion bags and in partially used medication vials.

Autoren: Arnamo AH Pluim D Huitema AD et al.

Quelle: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners [J Oncol Pharm Pract] 2025 Dec; Vol. 31 (8), pp. 1199-1209. Date of Electronic Publication: 2024 Aug 30.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: SAGE Publications Country of Publication: England NLM ID: 9511372 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1477-092X (Electronic) Linking ISSN: 10781552 NLM ISO Abbreviation: J Oncol Pharm Pract Subsets: MEDLINE

MeSH-Schlagworte: Antibodies, Monoclonal, Humanized*/chemistry , Antibodies, Monoclonal, Humanized*/administration & dosage , Nivolumab*/chemistry , Nivolumab*/administration & dosage , Drug Packaging* , Antineoplastic Agents, Immunological*/chemistry , Antineoplastic Agents, Immunological*/administration & dosage , Saline Solution*/chemistry, Drug Stability ; Drug Storage ; Infusions, Intravenous ; Humans ; Drug Compounding

Efficacy of adjuvant nivolumab in patients with upper tract predominant urothelial carcinoma: A single-center real-world study.

Autoren: Chen YC Lai JI Chang YH et al.

Quelle: Urologic oncology [Urol Oncol] 2025 Dec; Vol. 43 (12), pp. 697.e11-697.e18. Date of Electronic Publication: 2025 Aug 09.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: Elsevier Country of Publication: United States NLM ID: 9805460 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-2496 (Electronic) Linking ISSN: 10781439 NLM ISO Abbreviation: Urol Oncol Subsets: MEDLINE

MeSH-Schlagworte: Nivolumab*/therapeutic use , Nivolumab*/pharmacology , Antineoplastic Agents, Immunological*/therapeutic use , Carcinoma, Transitional Cell*/drug therapy , Carcinoma, Transitional Cell*/pathology , Carcinoma, Transitional Cell*/mortality , Kidney Neoplasms*/drug therapy , Kidney Neoplasms*/pathology , Kidney Neoplasms*/mortality , Ureteral Neoplasms*/drug therapy , Ureteral Neoplasms*/pathology , Ureteral Neoplasms*/mortality, Humans ; Male ; Female ; Aged ; Retrospective Studies ; Middle Aged ; Chemotherapy, Adjuvant ; Taiwan ; Treatment Outcome ; Aged, 80 and over

Nivolumab plus gemcitabine-cisplatin for previously untreated unresectable or metastatic urothelial carcinoma: an Asian subgroup analysis from the global phase 3 CheckMate 901 trial.

Autoren: Tomita Y Ye DW Fujii A et al.

Quelle: Urologic oncology [Urol Oncol] 2025 Dec; Vol. 43 (12), pp. 696.e9-696.e16. Date of Electronic Publication: 2025 Sep 26.

Publikationsart: Journal Article; Clinical Trial, Phase III; Randomized Controlled Trial; Multicenter Study

Info zur Zeitschrift: Publisher: Elsevier Country of Publication: United States NLM ID: 9805460 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-2496 (Electronic) Linking ISSN: 10781439 NLM ISO Abbreviation: Urol Oncol Subsets: MEDLINE

MeSH-Schlagworte: Deoxycytidine*/analogs & derivatives , Deoxycytidine*/administration & dosage , Deoxycytidine*/therapeutic use , Cisplatin*/therapeutic use , Cisplatin*/administration & dosage , Cisplatin*/pharmacology , Nivolumab*/therapeutic use , Nivolumab*/administration & dosage , Nivolumab*/pharmacology , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Carcinoma, Transitional Cell*/drug therapy , Carcinoma, Transitional Cell*/mortality , Carcinoma, Transitional Cell*/secondary , Carcinoma, Transitional Cell*/pathology , Urologic Neoplasms*/drug therapy , Urologic Neoplasms*/pathology , Urologic Neoplasms*/mortality , Urinary Bladder Neoplasms*/drug therapy , Urinary Bladder Neoplasms*/pathology, Humans ; Gemcitabine ; Male ; Female ; Aged ; Middle Aged ; Neoplasm Metastasis

GWAS Identifies SNPs Associated With Severe Adverse Events and Efficacy in Advanced Renal Cell Carcinoma Treated With Nivolumab.

Autoren: Tanegashima T Shiota M Akamatsu S et al.

Körperschaften: Tanegashima T Shiota M Akamatsu S et al.

Quelle: Cancer science [Cancer Sci] 2025 Dec; Vol. 116 (12), pp. 3300-3308. Date of Electronic Publication: 2025 Sep 24.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: Wiley Publishing on behalf of the Japanese Cancer Association Country of Publication: England NLM ID: 101168776 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1349-7006 (Electronic) Linking ISSN: 13479032 NLM ISO Abbreviation: Cancer Sci Subsets: MEDLINE

MeSH-Schlagworte: Nivolumab*/adverse effects , Nivolumab*/therapeutic use , Carcinoma, Renal Cell*/drug therapy , Carcinoma, Renal Cell*/genetics , Carcinoma, Renal Cell*/pathology , Carcinoma, Renal Cell*/mortality , Polymorphism, Single Nucleotide* , Kidney Neoplasms*/drug therapy , Kidney Neoplasms*/genetics , Kidney Neoplasms*/mortality , Kidney Neoplasms*/pathology , Immune Checkpoint Inhibitors*/adverse effects , Immune Checkpoint Inhibitors*/therapeutic use, Humans ; Male ; Genome-Wide Association Study ; Female ; Aged ; Middle Aged ; Prognosis ; Progression-Free Survival ; Biomarkers, Tumor/genetics ; Japan ; Aged, 80 and over ; Adult

A phase II study of nivolumab plus metformin in pre-treated metastatic renal cell carcinoma patients: NivoMet TWINS-GU002 Study.

Autoren: Ciccarese C Arduini D Primi F et al.

Quelle: Tumori [Tumori] 2025 Dec; Vol. 111 (6), pp. 523-528. Date of Electronic Publication: 2025 Oct 30.

Publikationsart: Journal Article; Clinical Trial, Phase II; Multicenter Study

Info zur Zeitschrift: Publisher: Sage Publications Country of Publication: United States NLM ID: 0111356 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2038-2529 (Electronic) Linking ISSN: 03008916 NLM ISO Abbreviation: Tumori Subsets: MEDLINE

MeSH-Schlagworte: Carcinoma, Renal Cell*/drug therapy , Carcinoma, Renal Cell*/pathology , Carcinoma, Renal Cell*/mortality , Nivolumab*/administration & dosage , Nivolumab*/adverse effects , Nivolumab*/therapeutic use , Metformin*/administration & dosage , Metformin*/adverse effects , Metformin*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects , Kidney Neoplasms*/drug therapy , Kidney Neoplasms*/pathology, Humans ; Male ; Female ; Middle Aged ; Aged ; Adult ; Prospective Studies ; Neoplasm Metastasis ; Treatment Outcome ; Progression-Free Survival

Cost-effectiveness of perioperative nivolumab + neoadjuvant platinum doublet chemotherapy as treatment for resectable non-small cell lung cancer in the United States.

Autoren: White B Harris M Villacorta R et al.

Quelle: Journal of medical economics [J Med Econ] 2025 Dec; Vol. 28 (1), pp. 625-637. Date of Electronic Publication: 2025 Apr 25.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: Taylor & Francis Country of Publication: England NLM ID: 9892255 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1941-837X (Electronic) Linking ISSN: 13696998 NLM ISO Abbreviation: J Med Econ Subsets: MEDLINE

MeSH-Schlagworte: Carcinoma, Non-Small-Cell Lung*/drug therapy , Carcinoma, Non-Small-Cell Lung*/surgery , Carcinoma, Non-Small-Cell Lung*/mortality , Carcinoma, Non-Small-Cell Lung*/pathology , Nivolumab*/economics , Nivolumab*/therapeutic use , Nivolumab*/administration & dosage , Lung Neoplasms*/drug therapy , Lung Neoplasms*/surgery , Lung Neoplasms*/mortality , Lung Neoplasms*/pathology , Neoadjuvant Therapy*/economics , Neoadjuvant Therapy*/methods , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/economics , Antineoplastic Agents, Immunological*/therapeutic use , Antineoplastic Agents, Immunological*/economics, Humans ; Cost-Benefit Analysis ; United States ; Quality-Adjusted Life Years ; Markov Chains ; Models, Econometric ; Chemotherapy, Adjuvant/economics

Long-term survival after resolution of pulmonary metastasis in a patient with unresectable cervical esophageal carcinoma after nivolumab-induced immune-related adverse events.

Autoren: Okamoto K Kikuchi D Yamashita S et al.

Quelle: Clinical journal of gastroenterology [Clin J Gastroenterol] 2025 Dec; Vol. 18 (6), pp. 1061-1067. Date of Electronic Publication: 2025 Aug 24.

Publikationsart: Journal Article; Case Reports

Info zur Zeitschrift: Publisher: Springer Japan Country of Publication: Japan NLM ID: 101477246 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1865-7265 (Electronic) Linking ISSN: 18657265 NLM ISO Abbreviation: Clin J Gastroenterol Subsets: MEDLINE

MeSH-Schlagworte: Nivolumab*/adverse effects , Nivolumab*/therapeutic use , Esophageal Neoplasms*/pathology , Esophageal Neoplasms*/therapy , Esophageal Neoplasms*/drug therapy , Lung Neoplasms*/secondary , Antineoplastic Agents, Immunological*/adverse effects , Antineoplastic Agents, Immunological*/therapeutic use , Esophageal Squamous Cell Carcinoma*/therapy , Esophageal Squamous Cell Carcinoma*/secondary , Esophageal Squamous Cell Carcinoma*/pathology, Humans ; Male ; Aged ; Chemoradiotherapy

Real-World Outcomes of Nivolumab Plus Ipilimumab Versus Pembrolizumab Plus Axitinib for First-Line Treatment of Advanced Renal Cell Carcinoma.

Autoren: Geynisman DM John WS Miller TA et al.

Quelle: Clinical genitourinary cancer [Clin Genitourin Cancer] 2025 Dec; Vol. 23 (6), pp. 102443. Date of Electronic Publication: 2025 Sep 25.

Publikationsart: Journal Article; Comparative Study

Info zur Zeitschrift: Publisher: Elsevier Country of Publication: United States NLM ID: 101260955 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1938-0682 (Electronic) Linking ISSN: 15587673 NLM ISO Abbreviation: Clin Genitourin Cancer Subsets: MEDLINE

MeSH-Schlagworte: Carcinoma, Renal Cell*/drug therapy , Carcinoma, Renal Cell*/mortality , Carcinoma, Renal Cell*/pathology , Axitinib*/administration & dosage , Axitinib*/therapeutic use , Nivolumab*/administration & dosage , Nivolumab*/therapeutic use , Antibodies, Monoclonal, Humanized*/administration & dosage , Antibodies, Monoclonal, Humanized*/therapeutic use , Kidney Neoplasms*/drug therapy , Kidney Neoplasms*/mortality , Kidney Neoplasms*/pathology , Ipilimumab*/administration & dosage , Ipilimumab*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects, Humans ; Male ; Female ; Middle Aged ; Retrospective Studies ; Aged ; Treatment Outcome ; Aged, 80 and over ; Adult ; Progression-Free Survival

Elevated proportion of eosinophils predicts immune-related adverse events and improved survival in patients with gastric cancer treated with nivolumab.

Autoren: Matsumoto S Nakade H Kunishige T et al.

Quelle: International journal of clinical oncology [Int J Clin Oncol] 2025 Dec; Vol. 30 (12), pp. 2587-2595. Date of Electronic Publication: 2025 Oct 29.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: Springer-Verlag Tokyo Country of Publication: Japan NLM ID: 9616295 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1437-7772 (Electronic) Linking ISSN: 13419625 NLM ISO Abbreviation: Int J Clin Oncol Subsets: MEDLINE

MeSH-Schlagworte: Stomach Neoplasms*/drug therapy , Stomach Neoplasms*/mortality , Stomach Neoplasms*/immunology , Stomach Neoplasms*/blood , Stomach Neoplasms*/pathology , Nivolumab*/adverse effects , Nivolumab*/administration & dosage , Eosinophils*/immunology , Eosinophils*/pathology , Immune Checkpoint Inhibitors*/adverse effects, Humans ; Male ; Female ; Middle Aged ; Aged ; Retrospective Studies ; Adult ; Aged, 80 and over

Uveitis associated with immunotherapy and its response to monotherapy with difluprednate: A case report.

Autoren: Ortega CM Pérez Bello AT Graizman Kohan BF et al.

Quelle: Archivos de la Sociedad Espanola de Oftalmologia [Arch Soc Esp Oftalmol (Engl Ed)] 2025 Dec; Vol. 100 (12), pp. 788-792. Date of Electronic Publication: 2025 Sep 27.

Publikationsart: Case Reports; Journal Article

Info zur Zeitschrift: Publisher: Elsevier España Country of Publication: Spain NLM ID: 101715860 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2173-5794 (Electronic) Linking ISSN: 21735794 NLM ISO Abbreviation: Arch Soc Esp Oftalmol (Engl Ed) Subsets: MEDLINE

MeSH-Schlagworte: Uveitis*/chemically induced , Uveitis*/drug therapy , Nivolumab*/adverse effects , Nivolumab*/therapeutic use , Ipilimumab*/adverse effects , Ipilimumab*/therapeutic use , Fluprednisolone*/therapeutic use , Fluprednisolone*/analogs & derivatives , Immune Checkpoint Inhibitors*/adverse effects , Immunotherapy*/adverse effects , Antineoplastic Agents, Immunological*/adverse effects , Antineoplastic Agents, Immunological*/therapeutic use, Humans ; Melanoma/drug therapy ; Melanoma/secondary ; Male ; Middle Aged ; Female

Final 3-year results from the EVIDENS study, an observational study of nivolumab in non-small cell lung cancer.

Autoren: Barlesi F Dixmier A Debieuvre D et al.

Quelle: Oncoimmunology [Oncoimmunology] 2025 Dec; Vol. 14 (1), pp. 2492932. Date of Electronic Publication: 2025 Apr 15.

Publikationsart: Journal Article; Observational Study

Info zur Zeitschrift: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101570526 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2162-402X (Electronic) Linking ISSN: 21624011 NLM ISO Abbreviation: Oncoimmunology Subsets: MEDLINE

MeSH-Schlagworte: Antineoplastic Agents, Immunological*/therapeutic use , Antineoplastic Agents, Immunological*/adverse effects , Carcinoma, Non-Small-Cell Lung*/drug therapy , Carcinoma, Non-Small-Cell Lung*/pathology , Carcinoma, Non-Small-Cell Lung*/mortality , Lung Neoplasms*/drug therapy , Lung Neoplasms*/pathology , Lung Neoplasms*/mortality , Nivolumab*/therapeutic use , Nivolumab*/adverse effects, Aged ; Female ; Humans ; Male ; France ; Longitudinal Studies ; Prospective Studies ; Quality of Life ; Treatment Outcome

Good response with nivolumab and cabozantinib combination therapy in patients with metastatic collecting duct carcinoma with high expression of PD-L1, c-MET, and AXL.

Autoren: Umemoto T Hasegawa M Naruse J et al.

Quelle: CEN case reports [CEN Case Rep] 2025 Dec; Vol. 14 (6), pp. 857-862. Date of Electronic Publication: 2025 Sep 08.

Publikationsart: Journal Article; Case Reports

Info zur Zeitschrift: Publisher: Springer Japan Country of Publication: Japan NLM ID: 101636244 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2192-4449 (Electronic) Linking ISSN: 21924449 NLM ISO Abbreviation: CEN Case Rep Subsets: MEDLINE

MeSH-Schlagworte: Anilides*/administration & dosage , Anilides*/therapeutic use , Carcinoma, Renal Cell*/drug therapy , Carcinoma, Renal Cell*/pathology , Nivolumab*/administration & dosage , Nivolumab*/therapeutic use , Kidney Neoplasms*/drug therapy , Kidney Neoplasms*/pathology , Pyridines*/administration & dosage , Pyridines*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use, Humans ; Male ; Axl Receptor Tyrosine Kinase ; Receptor Protein-Tyrosine Kinases/metabolism ; Middle Aged ; B7-H1 Antigen/metabolism ; Proto-Oncogene Proteins c-met/metabolism ; Proto-Oncogene Proteins/metabolism ; Female ; Aged ; Nephrectomy/methods ; Treatment Outcome

Real-world evidence of nivolumab monotherapy in advanced renal cell carcinoma from a multicenter retrospective cohort study by the Spanish Genitourinary Oncology Group.

Autoren: Fernández-Díaz N Mateos-González M Pertejo-Fernández A et al.

Quelle: BMC cancer [BMC Cancer] 2025 Nov 28; Vol. 25 (1), pp. 1835. Date of Electronic Publication: 2025 Nov 28.

Publikationsart: Journal Article; Multicenter Study

Info zur Zeitschrift: Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE

MeSH-Schlagworte: Nivolumab*/therapeutic use , Nivolumab*/administration & dosage , Carcinoma, Renal Cell*/drug therapy , Carcinoma, Renal Cell*/mortality , Carcinoma, Renal Cell*/pathology , Kidney Neoplasms*/drug therapy , Kidney Neoplasms*/mortality , Kidney Neoplasms*/pathology , Antineoplastic Agents, Immunological*/therapeutic use, Humans ; Male ; Female ; Retrospective Studies ; Middle Aged ; Aged ; Spain/epidemiology ; Adult ; Aged, 80 and over ; Treatment Outcome ; Progression-Free Survival

Proton Pump Inhibitors Attenuate the Effectiveness of Nivolumab Monotherapy in Patients with Advanced Gastric Cancer: A Retrospective Study.

Autoren: Yamaguchi M Kawazoe H Kasai Y et al.

Quelle: Journal of gastrointestinal cancer [J Gastrointest Cancer] 2025 Nov 21; Vol. 56 (1), pp. 226. Date of Electronic Publication: 2025 Nov 21.

Publikationsart: Journal Article; Observational Study

Info zur Zeitschrift: Publisher: Springer Country of Publication: United States NLM ID: 101479627 Publication Model: Electronic Cited Medium: Internet ISSN: 1941-6636 (Electronic) NLM ISO Abbreviation: J Gastrointest Cancer Subsets: MEDLINE

MeSH-Schlagworte: Nivolumab*/therapeutic use , Nivolumab*/pharmacology , Nivolumab*/administration & dosage , Stomach Neoplasms*/drug therapy , Stomach Neoplasms*/mortality , Stomach Neoplasms*/pathology , Proton Pump Inhibitors*/therapeutic use , Proton Pump Inhibitors*/adverse effects , Proton Pump Inhibitors*/administration & dosage , Proton Pump Inhibitors*/pharmacology , Antineoplastic Agents, Immunological*/therapeutic use, Humans ; Male ; Retrospective Studies ; Female ; Aged ; Middle Aged ; Aged, 80 and over ; Progression-Free Survival ; Japan/epidemiology ; Adult ; Treatment Outcome

Clinical and translational study of ivosidenib plus nivolumab in advanced solid tumors harboring IDH1 mutations.

Autoren: Nguyen MK Jelinek M Singh A et al.

Quelle: The oncologist [Oncologist] 2025 Nov 11; Vol. 30 (11).

Publikationsart: Journal Article; Clinical Trial, Phase II

Info zur Zeitschrift: Publisher: Oxford University Press Country of Publication: England NLM ID: 9607837 Publication Model: Print Cited Medium: Internet ISSN: 1549-490X (Electronic) Linking ISSN: 10837159 NLM ISO Abbreviation: Oncologist Subsets: MEDLINE

MeSH-Schlagworte: Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/pharmacology , Glycine*/analogs & derivatives , Glycine*/pharmacology , Glycine*/administration & dosage , Glycine*/therapeutic use , Glycine*/analogs & derivatives , Isocitrate Dehydrogenase*/genetics , Neoplasms*/drug therapy , Neoplasms*/genetics , Neoplasms*/pathology , Nivolumab*/pharmacology , Nivolumab*/therapeutic use , Nivolumab*/administration & dosage , Pyridines*/pharmacology , Pyridines*/therapeutic use , Pyridines*/administration & dosage, Adult ; Aged ; Female ; Humans ; Male ; Middle Aged ; Mutation ; Translational Research, Biomedical ; Tumor Microenvironment/drug effects

Recurrent Cytokine Release Syndrome in Metastatic Gastric Cancer on Nivolumab-FOLFOX: A Case Report and Mechanistic Review.

Autoren: Islam J Rashid Z Munster AB et al.

Quelle: Journal of gastrointestinal cancer [J Gastrointest Cancer] 2025 Nov 04; Vol. 56 (1), pp. 213. Date of Electronic Publication: 2025 Nov 04.

Publikationsart: Case Reports; Journal Article

Info zur Zeitschrift: Publisher: Springer Country of Publication: United States NLM ID: 101479627 Publication Model: Electronic Cited Medium: Internet ISSN: 1941-6636 (Electronic) NLM ISO Abbreviation: J Gastrointest Cancer Subsets: MEDLINE

MeSH-Schlagworte: Adenocarcinoma*/drug therapy , Antineoplastic Combined Chemotherapy Protocols*/adverse effects , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Cytokine Release Syndrome*/chemically induced , Cytokine Release Syndrome*/diagnosis , Cytokine Release Syndrome*/etiology , Nivolumab*/adverse effects , Nivolumab*/administration & dosage , Stomach Neoplasms*/drug therapy , Stomach Neoplasms*/pathology , Stomach Neoplasms*/immunology, Aged, 80 and over ; Female ; Humans ; Fluorouracil/adverse effects ; Fluorouracil/therapeutic use ; Leucovorin/adverse effects ; Leucovorin/therapeutic use ; Organoplatinum Compounds/adverse effects ; Organoplatinum Compounds/therapeutic use

SCR Protocol: Folfox protocol

Predictive value of homologous recombination-related gene mutations in survival outcomes of first-line nivolumab plus chemotherapy for gastric cancer.

Autoren: Lee Y Kim HD Lee SY et al.

Quelle: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association [Gastric Cancer] 2025 Nov; Vol. 28 (6), pp. 1158-1169. Date of Electronic Publication: 2025 Jul 28.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: Springer-Verlag Tokyo Country of Publication: Japan NLM ID: 100886238 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1436-3305 (Electronic) Linking ISSN: 14363291 NLM ISO Abbreviation: Gastric Cancer Subsets: MEDLINE

MeSH-Schlagworte: Stomach Neoplasms*/drug therapy , Stomach Neoplasms*/genetics , Stomach Neoplasms*/mortality , Stomach Neoplasms*/pathology , Nivolumab*/administration & dosage , Nivolumab*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Mutation* , Recombinational DNA Repair*/genetics, Humans ; Female ; Male ; Aged ; Middle Aged ; Adult ; Prognosis ; Aged, 80 and over ; Survival Rate ; Biomarkers, Tumor/genetics ; Retrospective Studies